摘要
本文旨在学习典型国家创新药医保谈判准入评价标准设计和框架,结合我国创新药医保谈判准入现状,为完善我国创新药医保谈判准入评价标准提供参考。查阅并总结新西兰、德国、法国创新药医保谈判准入相关的评价标准,分析其特点并与我国进行比较,探讨对我国的借鉴意义。典型国家在创新药医保谈判准入体系方面发展较为成熟,在评价内容的多样性、评价标准的科学性及谈判标准的透明度等方面值得借鉴。建议我国在评价标准设置上从以下方面进行完善:要求提交真实可信且可获得的成本分析数据供药物经济学评估研究使用,明确创新药医保谈判准入品种的评审标准,建立完善的风险控制机制。
The aim of the article was to provide references for improving the evaluation criteria of medical insurance negotiation admittance for innovative drugs by studying the design and framework of the evaluation criteria of medical insurance negotiation admittance for innovative drugs in typical countries,combined with the current situation in China.The relevant evaluation criteria of New Zealand,Germany,and France were reviewed and summarized,and their characteristics was analyzed and compared with that of China.The reference significance to our country was discussed.Typical countries are more mature in terms of the evaluation system of medical insurance negotiation admittance for innovative drugs,and the diversity of evaluation content,scientificity of evaluation criteria and transparency of negotiation criteria could provide references to our country.It is suggested that China should improve the setting of evaluation criteria from the following aspects:requirement to submit authentic and available cost analysis data for the use of pharmacoeconomic evaluation research,clarifying the evaluation criteria for the varieties of medical insurance negotiation admittance,and establishing good risk control mechanism.
作者
姚雯
颜建周
邵蓉
YAO Wen;YAN Jian-zhou;SHAO Rong(National Drug Policy and Medical Industry Economy Research Center of China Pharmaceutical University,Nanjing 211198,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2021年第12期1057-1062,共6页
Chinese Journal of New Drugs
基金
中国药科大学“双一流”学科创新团队建设项目(CPU2018GY40)。
关键词
典型国家
医保谈判
评价标准
新西兰
德国
法国
typical countries
medical insurance negotiation
evaluation criteria
New Zealand
Germany
France
